scholarly journals Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd

2017 ◽  
Vol 179 (2) ◽  
pp. 219-228 ◽  
Author(s):  
Timothy P. Hughes ◽  
Eduardo Munhoz ◽  
Marco Aurelio Salvino ◽  
Tee Chuan Ong ◽  
Alaa Elhaddad ◽  
...  
2020 ◽  
Vol 189 (2) ◽  
pp. 303-312 ◽  
Author(s):  
Young Rok Do ◽  
Jae‐Yong Kwak ◽  
Jeong A. Kim ◽  
Hyeoung Joon Kim ◽  
Joo Seop Chung ◽  
...  

2017 ◽  
Vol 13 (01) ◽  
pp. 15
Author(s):  
Ahmet Emre Eskazan ◽  

Although the management of patients with chronic myeloid leukaemia in chronic phase (CML-CP), especially in the newly-diagnosed patient, is generally straightforward, it may vary in the salvage setting, since some of the currently approved tyrosine kinase inhibitors are not available in some countries. This commentary mainly focuses on a questionnaire and the subsequent paper, which were performed in order to understand the perspectives of the CML-treating physicians from different countries in the management of refractory CML-CP.


2014 ◽  
Vol 168 (1) ◽  
pp. 69-81 ◽  
Author(s):  
Tim H. Brümmendorf ◽  
Jorge E. Cortes ◽  
Cármino Antonio Souza ◽  
Francois Guilhot ◽  
Ladan Duvillié ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document